819796-91-3

Upstream product

• 33125-05-2 Boc-D-Phg-OH 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 819796-92-4 (R)-2-tert-butoxycarbonylamino-1,2-diphenylethanone 
• 1192424-51-3 C₁₆H₂₁NO₃ 
• 1192424-53-5 C₁₁H₁₃NO*ClH 
• 1192424-55-7 C₂₂H₃₂N₂O₄S 
• 1192424-57-9 C₂₂H₃₁N₃O₂S 
• 1356606-53-5 (R)-tert-butyl 2-cyano-2-hydroxy-1-phenylethylcarbamate 
• 1356606-76-2 (R)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-hydroxy-3-phenylpropanoic acid 
• 161453-08-3 C₉H₁₁NO₃*ClH 
• 137284-11-8 (2R)-2-N-(tert-butoxycarbonyl)amino-2-phenylethanal 

Relevant academic research and scientific papers

COMPOUND HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY

This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is substituted or unsubstituted alkyl or the like, R2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.

COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY

This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is substituted or unsubstituted alkyl or the like, R2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.

Preparation of α-hydroxy-β-Fmoc amino acids from N-Boc amino acids

A general method for the conversion of N-Boc amino acids into their homologated α-hydroxy-β-Fmoc amino acids is described. The protocol involved preparation of the amino aldehyde by reduction of the corresponding Weinreb amides, hydrocyanation, and hydrol

Practical synthesis of fluorous oxazolidinone chiral auxiliaries from α-amino acids

A series of new fluorous-supported oxazolidinone chiral auxiliaries has been prepared using a versatile and general five-step pathway, starting from readily available chiral α-amino acids. The key feature of this synthesis is the efficient generation of a suitably active perfluoroalkyllithium species. By use of this protocol, the auxiliaries can be obtained in high enantiomeric purity and on multigram scales from L-phenylalanine and L-valine with overall yields as high as 55%. The new methodology also incorporates fluorous solid-phase extraction on the large scale, allowing bulk quantities (up to 25 g) of fluorous compounds to be purified from the crude reaction mixture.

Stille coupling of stereochemically defined α- sulfonamidoorganostannanes

Addition of tributylstannylmetallics to (R)-tert-butanesulfonimine derivatives of arylaldehydes provides α-sulfinamidostannanes with high (>98% de) diastereoselectivities. Oxidation of these compounds with m-CPBA gives α-sulfonamidostannanes which undergo Pd/Cu-catalyzed Stille-type couplings with benzoyl chloride. Best yields are achieved using the electron-rich tris(2,4,6-trimethoxyphenyl)phosphine as the ligand. Inversion of configuration at the benzylic carbon is observed. Copyright